Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06040541 · ClinicalTrials.gov registry record · Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

A Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines.

Recruiting
Registry status
Phase 1
Development phase
604
Enrollment target
17
Study locations

NCT06040541 is a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 604 participants, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (210% higher). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06040541, a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Revolution Medicines.

RECRUITING
Registry status
Phase 1
Development phase
604 participants
Enrollment target
17
Study locations

Study Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Conditions Studied

Advanced Solid Tumors Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

  • DRUG RMC-6236
  • DRUG RMC-9805

Study Locations (17)

Texas

  • Sarah Cannon Research Institute at Mary Crowley - Dallas
  • University of Texas, MD Anderson Cancer Center - Houston
  • START - San Antonio

Florida

  • Florida Cancer Specialists - Sarasota
  • Lee Moffitt Cancer Center - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

New York

  • NYU Langone - New York
  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Duke Cancer Center - Durham
  • Carolina BioOncology Institute - Huntersville

California

  • University of California, Davis Comprehensive Cancer Center - Sacramento

Connecticut

  • Smilow Cancer Hospital (Yale University) - New Haven

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 604 participants
Start Date 2023-09-07
Est. Completion 2027-04-30
Phase Phase 1

Sponsor

Revolution Medicines

16 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06040541

The ClinicalTrials.gov registry entry for NCT06040541 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 195-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (210% higher). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which RMC-6236 is the first listed.

NCT06040541 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Texas, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06040541 about?

NCT06040541 is a clinical study titled "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors". This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

What is the current status of trial NCT06040541?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 604 participants. The study started on 2023-09-07. Estimated completion is 2027-04-30.

What conditions does trial NCT06040541 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC).

What interventions are being tested in trial NCT06040541?

The interventions under investigation include: RMC-6236 (DRUG), RMC-9805 (DRUG).

Who is sponsoring clinical trial NCT06040541?

This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06040541 being conducted?

This trial has 17 study locations across California, Connecticut, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.